Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450799 | 0.89 | MCHR1 (0.49) | ADRB1CYP2D6HRH1KCNH2RORC | |
| SCHEMBL27389111 | 0.89 | MCHR1 (0.49) | ADRB1CYP2D6HRH1KCNH2RORC | |
| SCHEMBL14924424 | 0.89 | MCHR1 (0.49) | ADRB1CYP2D6HRH1KCNH2RORC | |
| SCHEMBL8726329 | 0.83 | L3MBTL3 (0.42) | KCNH2L3MBTL3MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL22837830 | 0.83 | HTR2A (0.43) | KCNH2L3MBTL3MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL578309 | 0.83 | NPY5R (0.49) | L3MBTL3L3MBTL1USP2EEDRORC | |
| SCHEMBL1409679 | 0.83 | MAPT (0.53) | L3MBTL3MAPTL3MBTL1ALDH1A1USP2 | |
| SCHEMBL5539933 | 0.83 | KDM4E (0.49) | L3MBTL3MAPTL3MBTL1ALDH1A1USP2 | |
| SCHEMBL5539924 | 0.83 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1USP2EEDRORC | |
| SCHEMBL21447979 | 0.82 | L3MBTL3 (0.52) | ADRB1L3MBTL3L3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-3838898-B1 | ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022236253-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236256-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022146201-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-07-07 | — | — | WO | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021254389-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
| EP-3838898-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | Korea Research Institute of Chemical Technology (KR) | 2021-06-23 | — | — | EP | disclosed |
| US-20170002013-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2017004408-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1.2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-9346801-B2 | Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | ADRB1 4531/4885CYP2D6 4459/4885HRH1 1862/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | ADRB1 2672/4885CYP2D6 1266/4885HRH1 1197/4885 |
| US-20170002013-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | ADRB1 4005/4885CYP2D6 1858/4885HRH1 2582/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | ADRB1 4512/4885CYP2D6 4505/4885HRH1 1956/4885 |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | DPYD, TYMP, TYMS | ADRB1 3177/4885CYP2D6 22/4885HRH1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.